[Secondary surfactant deficiencies].
Preterm babies born before the 33rd week of gestation often exhibit primary surfactant deficiency responsible for the respiratory distress syndrome or hyaline membrane disease. In that situation, there is a limited and insufficient production of surfactant by type II alveolar cells of the lung due to immaturity. Secondary surfactant deficiencies occur in patients with prior normal surfactant synthesis and can be related to sepsis, hypoxia, ventilator induced lung injury or surfactant inhibition by a variety of substances reaching the alveolar spaces. They occur in full-term newborns with meconium aspiration syndrome, acute respiratory distress syndrome and congenital diaphragmatic hernia. In children and adults, acute respiratory distress syndrome and respiratory syncytial virus bronchiolitis can be responsible. In prematures they occur after the initial primary deficiency during pulmonary hemorrhage, pneumonia and bronchopulmonary dysplasia. Treatment with exogenous surfactant may be beneficial. There is a need for randomized controlled studies for evaluation of this treatment. Next generation of surfactants containing recombinant surfactant protein or synthetic peptides appear as promising agents in these situations of secondary surfactant deficiencies.
Escande
B
B
Service de pédiatrie-II, médecine néonatale et réanimation pédiatrique, hôpital de Hautepierre, hôpitaux universitaires de Strasbourg, avenue Molière, 67098 Strasbourg cedex, France.
Kuhn
P
P
Rivera
S
S
Messer
J
J
D000328:Adult; D001997:Bronchopulmonary Dysplasia / Q000150:complications; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008171:Lung Diseases / Q000150:complications; D008471:Meconium Aspiration Syndrome / Q000150:complications; D011663:Pulmonary Surfactants / Q000032:analysis / Q000494:pharmacology* / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000209:etiology*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy* / Q000209:etiology*
D011663:Pulmonary Surfactants